Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

Related Parents

Related Issuers

PRICED: Sanofi US$3bn 5-Part

IGC European Market: Deal Flow - GeneralIGC US Market: Deal Flow - General

Sanofi SA (SANFP), exp Aa3/AA/AA (s/s/s) by Moody's/S&P/Scope, US$3bn SEC registered 5-part sr notes (2y FXD and/or FRN due 11/3/27, 3y FXD and/or FRN due 11/3/28 and 7y FXD due 11/3/32). MWC on FXD tranches. 1mo par call on 3y and 2mos on 7y. Barc/BNP/BofA as joint global coordinators. Active joint books: Barc/BNP/BofA (B&D)/JPM/MUFG/MS/Natixis. First Pay FXD tranches: 5/3/26. Day Count FXD tranches: 30/360. Denominations: 2,000 x 1,000. Law / Listing: State of New York / None. Sale into Canada Yes - Exemption. UOP: General Corporate Purposes. Pricing 10/27. Settle 11/3 (T+5). CUSIP: 2y FXD: 801060AE4, 2y FRN: 801060AF1, 3y FXD: 801060AG9, 3y FRN: 801060AH7, 7y: 801060AJ3. ISIN: 2y FXD: US801060AE44, 2y FRN: US801060AF19, 3y FXD: US801060AG91, 3y FRN: US801060AH74, 7y: US801060AJ31.

IPTs: 2y T+45 area and SOFR equiv, 3y T+50 area and SOFR equiv, 7y T+70 area.
GUIDANCE: 2y FXD T+25#, 2y FRN SOFR+46#, 3y FXD T+30#, 3y FRN SOFR+54#, 7y T+45#.
LAUNCHED: $500m 2y FRN at SOFR+46, $400m 2y FXD at T+25, $500m 3y FRN at SOFR+54, $400m 3y FXD at T+30, $1.2bn 7y at T+45.

PRICED:
$500m 11/3/27 FRN at SOFR+46, at 100.
$400m 3.75% 11/3/27 99.998 3.751% T+25. MW+5.
$500m 11/3/28 FRN at SOFR+54, at 100.
$400m 3.80% 11/3/28 99.994 3.802% T+30. MW+5.
$1.2bn 4.20% 11/3/32 99.790 4.235% T+45. MW+10.


*** NETROADSHOW INFO ON SANFP ***


* Deputy CFO of Sanofi Olivier Klaric is avaialble for calls


* NETROADSHOW LINK:

http://www.netroadshow.com/nrs/home/#!/?show=c715d59e (recommended) or

https://www.netroadshow.com with entry Code: Sanfp25 (not case-sensitive)

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.